Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq: HCM) (AIM: HCM) (HKEX: 13) announced on Wednesday that it has completed patient enrollment for SANOVO, its China Phase III trial evaluating ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) as a first-line treatment for patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutations and MET overexpression. The final patient was enrolled on 18 August 2025.

SANOVO is a blinded, randomised, controlled study comparing the efficacy and safety of the ORPATHYS plus TAGRISSO combination against TAGRISSO monotherapy, a standard-of-care option. The primary endpoint is progression-free survival, with secondary measures including overall survival, objective response rate and safety. Topline results are expected in H2 2026, with potential submission to China's National Medical Products Administration if outcomes are positive.

ORPATHYS, a selective MET tyrosine kinase inhibitor, is co-developed and commercialised in China by AstraZeneca and HUTCHMED. TAGRISSO, AstraZeneca's third-generation EGFR-TKI, is a globally established therapy across multiple stages of EGFR-mutated NSCLC.

The SANOVO trial builds on promising results from earlier studies, including TATTON and SAVANNAH, and follows recent China approval of the ORPATHYS and TAGRISSO combination in June 2025 for EGFR mutation-positive NSCLC patients with MET amplification after EGFR TKI progression.

HUTCHMED is advancing multiple late-stage oncology programmes, with three medicines already marketed in China and international approvals secured in the US, Europe and Japan.